Immunexpress’ rapid test for sepsis launched in Europe on Biocartis’ Idylla platform

Debiopharm’s investment portfolio company Immunexpress’ rapid test for sepsis launched in Europe on Biocartis’ Idylla platform.

SeptiCyte® RAPID is a one-hour molecular diagnostic test running on the Biocartis Idylla platform that can swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients. This is the first rapid, fully-integrated, immune response-based test to aid clinicians with sepsis diagnosis.

This launch follows the CE marking announced in March 2020.

Access the full press release here